Clinical trial treatments typically consist of several phases, with each phase focused on a different purpose. Most of the time, when you take part in a clinical trial, you will only be in that one phase of the study. Treatments move through the phases, but patients do not.
The goal of a Phase I trial is to determine the safety of the new treatment, learn the best way to administer the treatment (orally, intravenously, etc.) and to see whether or not the cancer responds.
Phase I trials usually include 15 to 30 patients, divided into small groups called cohorts. When the first cohort receives a dose of the new drug, doctors may collect blood or urine samples to measure the drug levels.
If no severe side effects present themselves, the next cohort will receive a higher dose of the same drug. This continues with each new cohort until the best dose is determined. With each increasing dose, doctors test each patient to see if he or she is responding to the protocol treatment. If the doctors find that the treatment is safe, then the trial will move forward to be studied in a Phase II trial.
The average length of a Phase I clinical trial can be relatively short due to it being an introductory phase.
Typically, a Phase II trial has less than 100 patients. While the main goal is to see if the treatment works, doctors still closely watch for side effects. If the new treatment works, doctors may go on to study it in a Phase III trial.
The average length of a Phase II clinical trial can range from less than a year to up to two years.
Phase III trials typically include a high number of patients. Hundreds or even thousands of patients around the country or world may participate. Patients enrolled in a Phase III clinical trial will be placed into one of the following groups:
Common questions patients have include:
A computer program will randomly assign patients into groups. This helps to avoid bias in the clinical trial. (Bias happens when human choices affect a study’s results.)
It depends on the trial. For a single blind study, patients do not know which group they are in, but their doctor does. For a double-blind study, neither the patient nor their doctors know which group the patient is in. (In case of an emergency, however, doctors can receive this information.)
A placebo is something that looks like medicine but isn’t. If a placebo is used, it is administered along with the best standard treatment. Using a placebo allows doctors to compare standard treatment alone to standard treatment with a new drug. If there isn’t a standard treatment, then the placebo may be given alone, but this is uncommon.
After the Phase III trial, the FDA reviews the clinical trial results to make sure the treatment is safe and effective for people to use. The FDA decides whether to approve the treatment so that it is available for all patients.
The average length of a Phase III clinical trial can vary, ranging from one to four years or longer.
In Phase IV trials, doctors study treatments that the FDA has already approved. The goal of Phase IV trials is to continue studying any side effects of a new treatment.
The average length of a Phase IV clinical trial is usually shorter than Phase III so typically fewer than four years.
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (ELEVATE) (NCT04883905)
Principal Investigator: Dr. Danielle Nance
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease (NCT04114981)
Principal Investigator: Josh Niska
Locations: Banner MD Anderson Cancer Center at Banner Thunderbird Medical Center and Banner MD Anderson Cancer Center at Banner - University Medical Center Phoenix
Glioblastoma
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (NCT04471844)
Principal Investigator: Terrence Roberts
Locations: Banner MD Anderson Cancer Center at Banner Thunderbird Medical Center and Banner MD Anderson Cancer Center at Banner - University Medical Center Phoenix
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (NCT03488693)
Principal Investigator: Supriya Jain
Locations: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (NCT04457596)
Principal Investigator: Shakeela Bahadur (AZ), Esther Mondo (NoCo)
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy (NCT04975308)
Principal Investigators: Shakeela Bahadur (AZ), Esther Mondo (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Inflammatory Breast Cancer (IBC) Registry (NCT00477100)
Principal Investigators: Shakeela Bahadur AZ), Esther Mondo (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at Banner Boswell Medical Center, Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain (NCT04169542)
Principal Investigators: Molly Decker (NoCo)
Locations: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Prospective comparison of MRI versus contrast enhanced mammography prior to surgery in breast cancer patients: a randomized controlled trial (NCT04770714)
Principal Investigator: Michael Morris
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center and Banner MD Anderson Cancer Center at Banner - University Medical Center Phoenix
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer (NCT02912312)
Principal Investigators: Emily Grade (AZ), Supriya Jain (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Cervical Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Endometrial Cancer
Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer (NCT02397083)
Principal Investigator: Robin Lacour
Locations: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Ovarian Cancer and Endometrial Cancer
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Colorectal Cancer
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C) (NCT04739072)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy (NCT04793958)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (NCT05141721)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Colorectal, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Gastric/GEJ
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection (NCT04742907)
Principal Investigator: Michael Choti
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Solid Tumor
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer (NCT04698915)
Principal Investigator: Gary Walker
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04396821)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Subjects With Advanced Malignant Solid Tumors (NCT05266612)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (NCT04123366)
Principal Investigator: Sheakeela Bahadur
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor (NCT04987203)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Bladder Urothelial
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05215574)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (NCT03775265)
Principal Investigator: Eric Anderson
Location: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) (NCT05538663)
Principal Investigator: Chinedu Mmeje
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2 (NCT04879329)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Germ Cell Tumor
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors (NCT04435756)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Metastatic Renal Cell Carcinoma
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) (NCT04510597)
Principal Investigator: Chinedu Mmeje
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Prostate Cancer
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)(NCT04037254)
Principal Investigator: Alex Bowman
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) (NCT04513717)
Principal Investigator: Eric Anderson
Location: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NCT05050084)
Principal Investigator: Eric Anderson
Location: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT03574571)
Principal Investigator: Santosh Rao
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer (NCT03678025)
Principal Investigator: Chinedu Mmeje (AZ), Supriya Jain (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Solid Tumor
EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial assessing the efficacy of upfront local consolidative therapy (LCT) for oligometastatic disease (NCT03599765)
Principal Investigators: Gary Walker (AZ), Supriya Jain (NoCo)
Locations: Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Banner MD Anderson Cancer Center at Banner Thunderbird Medical Center, Banner MD Anderson Cancer Center at McKee Medical Center, Banner MD Anderson Cancer Center at North Colorado Medical Center
A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Previously Untreated Locally Advanced HNSCC (NCT04651634)
Principal Investigator: Gary Walker
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Solid Tumor
A Phase I/II Study of HB-201 Monotherapy or in Combination with Nivolumab in Patients with Human Papillomavirus 16 Positive (HPV 16+) Confirmed Cancers (NCT04180215)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Squamous Cell Carcinoma
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT04533750)
Principal Investigator: Michael Samuels
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (NCT03969004)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1 Study of PBCAR19B in Participants With CD19-expressing Malignancies (NCT04649112)
Principal Investigator: Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Adenovirus Infection
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation (NCT05179057)
Principal Investigator: Aileen Go
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML (NCT04358393)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic(NCT03386513)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT04067336)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Acute Myeloid Leukemia (AML)
Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage (NCT03926624)
Principal Investigator: Dr. Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217)
Principal Investigator: Dr. Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (NCT02194738)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Boswell Medical Center
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1) (NCT04476797)
Principal Investigator: Supriya Jain
Location: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC (NCT04214262)
Principal Investigator: Supriya Jain
Location: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Small Cell Lung Cancer
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (NCT04155034)
Principal Investigator: Supriya Jain
Location: Banner MD Anderson Cancer Center at McKee Medical Center and Banner MD Anderson Cancer Center at North Colorado Medical Center
Solid Tumor
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Dr. Jiaxin Niu
"A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer" (NCT04123366)
Principal Investigator: Sheakeela Bahadur
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (NCT04989803)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (NCT04792489)
Principal Investigator: Matthew Ulrickson
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Principal Investigator: Dr. Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
ALLO-501A-201: A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO--501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) (NCT04416984)
Principal Investigator: Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase I, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor (NCT05038150)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05215574)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer (NCT03674567)
Principal Investigator: Tomislav Dragovich
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05215574)
Principal Investigator: Madappa Kundranda
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma (NCT04184050)
Principal Investigator: Sumit Madan
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma (NCT04093596)
Principal Investigator: Rajneesh Nath
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors (NCT03767348)
Principal Investigator: Jiaxin Niu
Location: Banner MD Anderson Cancer Center at Banner Gateway Medical Center
Sign in to Patient Account
